Nanomix Corporation (NNMX)

OTCMKTS: NNMX · Delayed Price · USD
0.0700 0.0121 (20.90%)
Jan 14, 2022 4:00 PM EST - Market closed
Market Cap64.18M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out916.92M
EPS (ttm)n/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume819,333
Open0.0257
Previous Close0.0579
Day's Range0.0700 - 0.0700
52-Week Range0.0081 - 0.1870
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About NNMX

Boston Therapeutics, Inc. develops, manufactures, and commercializes therapeutic drugs to address unmet medical needs in diabetes and inflammatory diseases. The company develops BTI-320, a non-systemic carbohydrate-based compound tablet that is in Phase II clinical trial for reduction of post-meal blood glucose levels in pre-diabetes patients and type 2 diabetes patients; and IPOXYN, an injectable drug to prevent necrosis, as well as to treat hypoxic conditions, such as diabetic foot ulcers and other vascular/neurological complications. It is a...

IndustryMedical Devices
Founded2009
CountryUnited States
Stock ExchangeOTCMKTS
Ticker SymbolNNMX
Full Company Profile

News

There is no news available yet.